Cemiplimab, a human monoclonal antibody to PD-1, in patients with advanced cutaneous squamous cell carcinoma (CSCC): Clinical experience from the phase 1 and phase 2 studies

2019 ◽  
Vol 81 (4) ◽  
pp. AB31
Keyword(s):  
Monoclonal Antibody ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Clinical Experience ◽  
Squamous Cell ◽  
Phase 1 ◽  
Human Monoclonal Antibody ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Phase 2

Interim Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Antibody to Programmed Death-1, in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma

2018 ◽  
Vol 2 ◽  
pp. S77
Author(s):  
Michael R Migden ◽  
Carola Berkin ◽  
Anne Lynn Chang ◽  
Et Al.
Keyword(s):  
Monoclonal Antibody ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Interim Analysis ◽  
Human Monoclonal Antibody ◽  
Locally Advanced ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Phase 2 ◽  
Programmed Death ◽  
Programmed Death 1

Abstract not available. Disclosures: Study sponsored by Regeneron Pharmaceuticals and Sanofi. Copyright 2018 SKIN

scholarly journals Cemiplimab (REGN2810), a Fully Human Anti-PD-1 Monoclonal Antibody, for Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: Initial Safety and Efficacy from Expansion Cohorts of Phase 1 Study

2018 ◽  
Vol 2 ◽  
pp. S45
Author(s):  
Kyriakos P Papadopoulos ◽  
Taofeek K Owonikoko ◽  
Melissa L Johnson ◽  
Irene Brana ◽  
Marta Gil-Martin ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Phase 1 ◽  
Locally Advanced ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Phase 1 Study ◽  
Safety And Efficacy

Abstract not available. Disclosures: Study sponsored by Regeneron Pharmaceuticals Inc. and Sanofi. Copyright 2018 SKIN

Primary analysis of phase 2 results for cemiplimab, a human monoclonal anti-PD-1, in patients with metastatic cutaneous squamous cell carcinoma (mCSCC).

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 9519-9519 ◽  
Author(s):  
Danny Rischin ◽  
Michael Robert Migden ◽  
Anne Chang ◽  
Christine H. Chung ◽  
Lara Dunn ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Phase 2 ◽  
Primary Analysis

scholarly journals Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial

2020 ◽  
Vol 21 (2) ◽  
pp. 294-305 ◽  
Author(s):  
Michael R Migden ◽  
Nikhil I Khushalani ◽  
Anne Lynn S Chang ◽  
Karl D Lewis ◽  
Chrysalyne D Schmults ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Locally Advanced ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Phase 2 ◽  
Open Label ◽  
Open Label Phase

scholarly journals Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial

Cancer ◽  
2018 ◽  
Vol 124 (10) ◽  
pp. 2169-2173 ◽  
Author(s):  
Kathryn A. Gold ◽  
Merrill S. Kies ◽  
William N. William ◽  
Faye M. Johnson ◽  
J. Jack Lee ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Phase 2 ◽  
Phase 2 Clinical Trial

scholarly journals Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up

2020 ◽  
Vol 4 (6) ◽  
pp. s124
Author(s):  
Danny Rischin ◽  
Nikhil Khushalani ◽  
Chryslalyne Schmults ◽  
Alexander Guminski ◽  
Anne Lynn Chang ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Phase 2 ◽  
Phase 2 Study

Abstract not available.

Primary Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients with Metastatic Cutaneous Squamous Cell Carcinoma

2018 ◽  
Vol 2 ◽  
pp. S79
Author(s):  
Danny Rischin ◽  
Michael R Migden ◽  
Anne Lynn S Chang ◽  
Et Al.
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Phase 2 ◽  
Primary Analysis

Abstract not available. Disclosures: Study sponsored by Regeneron Pharmaceuticals and Sanofi. Copyright 2018 SKIN

Sign in / Sign up

Export Citation Format

Share Document